Christina Schröter obtained her degree in Molecular Biotechnology from the Technical University of Munich in December 2024. In 2025, she joined the siRNA therapeutics team at Novartis in Basel, where she worked on establishing a 3D cell culture model to screen long-acting siRNAs. 
In January 2026, she joined the Pharmaceutical Technology group of Prof. Dr. J. Huwyler at the University of Basel as a PhD student, focusing on the development of an inorganic particulate drug delivery platform.